Meet Wuxi Biologics, the contract drugs maker that believes it can help cure China’s scandal-hit vaccine market
- Wuxi Biologics is in talks with three separate vaccine developers to manufacture their products in China
- ‘We already have a globally accepted quality assurance system … we can play a leading role in elevating vaccine standards,’ says chief executive
Wuxi Biologics, China’s largest biologic drugs services company, is in talks to sign contracts for the development of three potential vaccinations, in a bid to grab a slice of the nation’s scandal-hit market.
The firm, based in Wuxi, Jiangsu province, is negotiating with three separate vaccine developers on service contracts, said its chief executive Chris Chen Zhisheng. But it does not expect to generate any “meaningful revenue” from them until around 2021.
“The fundamental issues in the industry are quality-control related,” he said in an interview earlier this month on the sidelines of the JPMorgan healthcare conference in San Francisco.
“As the only company in China that can produce biologics biopharmaceutical products for the global market, we already have a globally accepted quality assurance system … we can play a leading role in elevating vaccine standards.”
Biologics, also known as biopharmaceuticals, are drugs produced from or containing components of living organisms. They include blood components, cells and proteins extracted from humans, animals and microorganisms and made into products to treat or prevent a variety of medical conditions.
